BioCentury | Nov 30, 2020
Finance

Kinaset jumps into severe asthma with $40M to develop inhaled JAK inhibitor

Kinaset is launching with a $40 million series A led by  5AM Ventures and Atlas Venture with participation from Gimv to develop an inhaled immunomodulator that will compete with biologics in severe...
BioCentury | Nov 25, 2020
Product Development

Data Byte: a snapshot of the clinical cutaneous T cell lymphoma pipeline

At least 14 therapies are in the clinic to treat cutaneous T cell lymphoma, a rare cancer of T lymphocytes that primarily affects the skin. The most common subtypes of CTCL are mycosis fungoides and...
BioCentury | Nov 24, 2020
Product Development

ASH preview & long shot drug pricing rules: a BioCentury podcast

On the latest edition of the BioCentury This Week podcast, BioCentury editors discuss how emerging targets, modalities and indications are stacking up at the upcoming American Society of Hematology meeting, as well as the uncertain...
BioCentury | Nov 24, 2020
Product Development

Nov. 23 Quick Takes: NIH panel says bamlanivimab should not be considered COVID-19 SOC; plus Eiger, Shionogi-Roche, Kiniksa, Schrödinger, Halozyme-Horizon and Immunicum-DCPrime

NIH panel says bamlanivimab should not be considered standard-of-care for COVID-19NIH’s COVID-19 Treatment Guidelines Panel said there is not enough data to recommend either for or against use of bamlanivimab from Eli Lilly and Co. (NYSE:LLY)...
BioCentury | Nov 24, 2020
Deals

OncoImmune's choice to repurpose GvHD program for COVID pays off via $425M takeout by Merck

OncoImmune’s move to repurpose its GvHD program for COVID-19 has paid off via a takeout by Merck for $425 million up front. Under the deal, which includes undisclosed milestones and royalties, Merck & Co. Inc....
BioCentury | Nov 23, 2020
Product Development

Immunocore charts the path for bispecifics in solid tumors with Phase III readout

With a positive Phase III readout in metastatic uveal melanoma, Immunocore has become the first company to solve one of the biggest challenges in immuno-oncology: applying T cell-engaging bispecifics to solid tumors.  The data suggest...
BioCentury | Nov 21, 2020
Regulation

Nov. 20 Quick Takes: Approvals in Europe for Alnylam, Alexion therapies; plus FDA priority review for ADC, Sanofi and more

EC approves Alnylam, Alexion therapiesAlnylam Pharmaceuticals Inc. (NASDAQ:ALNY) said the European Commission approved Oxlumo lumasiran, an RNAi therapy targeting the HAO1 mRNA that encodes glycolate oxidase, to treat primary hyperoxaluria in all age groups. The...
BioCentury | Nov 21, 2020
Finance

Mei readies Antengene to take its next steps to becoming a global biotech

Fresh off its $360 million IPO on the Hong Kong stock exchange, Shanghai’s Antengene is looking to take the next step in its evolution by building out its pipeline and launching its first drug....
BioCentury | Nov 20, 2020
Product Development

Phase III COVID-19 vaccine data kick-start next phase: mapping efficacy to antibody levels

Efficacy data from the first two Phase III trials of COVID-19 vaccines shattered expectations and validated mRNA as a vaccine modality. The findings also mark the start of the search for correlates of protection. An...
BioCentury | Nov 19, 2020
Finance

VCs back Celleron spinout with €37M to develop former Roche asset for rare joint disorder

A European VC syndicate shared Celleron’s belief that a single-asset start-up was the best place to develop emactuzumab, an asset the U.K. biotech obtained after Roche deprioritized it in 2018. The group supplied €37 million ($43.9...
Items per page:
1 - 10 of 12604